Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating. They now have a $175.00 price target on the stock, up previously from $156.00.
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024 [Yahoo! Finance]
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand [Yahoo! Finance]
SciBase welcomes new chairman and thanks the former [Yahoo! Finance]